EOLSEvolus, Inc.
$7.79+24% 1Y
$7.79
$3.9452 weeks$9.30
EOLS in its own filings
Nothing in EOLS's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
175
Events found in the filings · across 555 filings · the record starts in 2017
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 26, 2017
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- SEC comment-letter activity27 occurrences
- 2026-06-10
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook.Earnings release · press release
- Aug 4, 2026Symatese License Amendment - Addition of Australia, New Zealand and Canada On August 3, 2026, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”), and Symatese Aesthetics S.A.S. (“Symatese”) entered into an amendment (the “Amendment”) to the License, Supply and Distribution …Material agreement entered · Form 8-K
- Jul 8, 2026IBSA License Agreement - Profhilo ® On July 7, 2026, Evolus, Inc. (the “Company”) and IBSA Institut Biochimique SA (“IBSA”) entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute …Material agreement entered · Form 8-K
- May 4, 2026Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook.Earnings release · press release
- Mar 13, 2026Director Reclassification As previously disclosed, Simone Blank stepped down from the board of directors (the “Board”) of Evolus, Inc. (the “Company”) to support the Company’s board refreshment efforts.Director or officer change · Form 8-K
- Mar 3, 2026On March 3, 2026, Evolus, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Eclipse Business Capital LLC, as administrative agent (the “Agent”) and the lenders party thereto.Material agreement entered · Form 8-K
- Jan 9, 2026Evolus Announces Preliminary Unaudited Fourth Quarter.Earnings release · press release
- Nov 5, 2025Evolus Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Sep 8, 2025Appointment of Chief Financial Officer On September 8, 2025, Evolus, Inc. (the “Company”) announced that, effective September 8, 2025, its Board of Directors (the “Board”) appointed Tatjana Mitchell to serve as the Company’s Chief Financial Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #35 of 41 by RyuScore